A Clinical Study Provides the First Direct Evidence That Interindividual Variations in Fecal β-Lactamase Activity Affect the Gut Mycobiota Dynamics in Response to β-Lactam Antibiotics
Fungal infections are redoubtable healthcare-associated complications in immunocompromised patients. Particularly, the commensal intestinal yeast Candida albicans causes invasive infections in intensive care patients and is, therefore, associated with high mortality. Antibiotics disturb the intestin...
Saved in:
| Published in | mBio Vol. 13; no. 6; p. e0288022 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
20.12.2022
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2150-7511 2161-2129 2150-7511 |
| DOI | 10.1128/mbio.02880-22 |
Cover
| Abstract | Fungal infections are redoubtable healthcare-associated complications in immunocompromised patients. Particularly, the commensal intestinal yeast
Candida albicans
causes invasive infections in intensive care patients and is, therefore, associated with high mortality.
Antibiotics disturb the intestinal bacterial microbiota, leading to gut dysbiosis and an increased risk for the overgrowth of opportunistic pathogens. It is not fully understood to what extent antibiotics affect the fungal fraction of the intestinal microbiota, the mycobiota. There is no report of the direct role of antibiotics in the overgrowth in healthy humans of the opportunistic pathogenic yeast
Candida albicans
. Here, we have explored the gut mycobiota of 22 healthy subjects before, during, and up to 6 months after a 3-day regimen of third-generation cephalosporins (3GCs). Using ITS1-targeted metagenomics, we highlighted the strong intra- and interindividual diversity of the healthy gut mycobiota. With a specific quantitative approach, we showed that
C. albicans
prevalence was much higher than previously reported, with all subjects but one being carriers of
C. albicans
, although with highly variable burdens. 3GCs significantly altered the mycobiota composition and the fungal load was increased both at short and long term. Both
C. albicans
relative and absolute abundances were increased but 3GCs did not reduce intersubject variability. Variations in
C. albicans
burden in response to 3GC treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity, with subjects characterized by a high increase of β-lactamase activity displaying a lower increase of
C. albicans
levels. A same antibiotic treatment might thus affect differentially the gut mycobiota and
C. albicans
carriage, depending on the treated subject, suggesting a need to adjust the current risk factors for
C. albicans
overgrowth after a β-lactam treatment.
IMPORTANCE
Fungal infections are redoubtable healthcare-associated complications in immunocompromised patients. Particularly, the commensal intestinal yeast
Candida albicans
causes invasive infections in intensive care patients and is, therefore, associated with high mortality. These infections are preceded by an intestinal expansion of
C. albicans
before its translocation into the bloodstream. Antibiotics are a well-known risk factor for
C. albicans
overgrowth but the impact of antibiotic-induced dysbiosis on the human gut mycobiota—the fungal microbiota—and the understanding of the mechanisms involved in
C. albicans
overgrowth in humans are very limited. Our study shows that antibiotics increase the fungal proportion in the gut and disturb the fungal composition, especially
C. albicans
, in a subject-dependent manner. Indeed, variations across subjects in
C. albicans
burden in response to β-lactam treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity. This highlighted a potential new key factor for
C. albicans
overgrowth. Thus, the significance of our research is in providing a better understanding of the factors behind
C. albicans
intestinal overgrowth, which might lead to new means to prevent life-threatening secondary infections. |
|---|---|
| AbstractList | Antibiotics disturb the intestinal bacterial microbiota, leading to gut dysbiosis and an increased risk for the overgrowth of opportunistic pathogens. It is not fully understood to what extent antibiotics affect the fungal fraction of the intestinal microbiota, the mycobiota. There is no report of the direct role of antibiotics in the overgrowth in healthy humans of the opportunistic pathogenic yeast Candida albicans. Here, we have explored the gut mycobiota of 22 healthy subjects before, during, and up to 6 months after a 3-day regimen of third-generation cephalosporins (3GCs). Using ITS1-targeted metagenomics, we highlighted the strong intra- and interindividual diversity of the healthy gut mycobiota. With a specific quantitative approach, we showed that C. albicans prevalence was much higher than previously reported, with all subjects but one being carriers of C. albicans, although with highly variable burdens. 3GCs significantly altered the mycobiota composition and the fungal load was increased both at short and long term. Both C. albicans relative and absolute abundances were increased but 3GCs did not reduce intersubject variability. Variations in C. albicans burden in response to 3GC treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity, with subjects characterized by a high increase of β-lactamase activity displaying a lower increase of C. albicans levels. A same antibiotic treatment might thus affect differentially the gut mycobiota and C. albicans carriage, depending on the treated subject, suggesting a need to adjust the current risk factors for C. albicans overgrowth after a β-lactam treatment.
Fungal infections are redoubtable healthcare-associated complications in immunocompromised patients. Particularly, the commensal intestinal yeast Candida albicans causes invasive infections in intensive care patients and is, therefore, associated with high mortality. These infections are preceded by an intestinal expansion of C. albicans before its translocation into the bloodstream. Antibiotics are a well-known risk factor for C. albicans overgrowth but the impact of antibiotic-induced dysbiosis on the human gut mycobiota-the fungal microbiota-and the understanding of the mechanisms involved in C. albicans overgrowth in humans are very limited. Our study shows that antibiotics increase the fungal proportion in the gut and disturb the fungal composition, especially C. albicans, in a subject-dependent manner. Indeed, variations across subjects in C. albicans burden in response to β-lactam treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity. This highlighted a potential new key factor for C. albicans overgrowth. Thus, the significance of our research is in providing a better understanding of the factors behind C. albicans intestinal overgrowth, which might lead to new means to prevent life-threatening secondary infections. Antibiotics disturb the intestinal bacterial microbiota, leading to gut dysbiosis and an increased risk for the overgrowth of opportunistic pathogens. It is not fully understood to what extent antibiotics affect the fungal fraction of the intestinal microbiota, the mycobiota. There is no report of the direct role of antibiotics in the overgrowth in healthy humans of the opportunistic pathogenic yeast Candida albicans. Here, we have explored the gut mycobiota of 22 healthy subjects before, during, and up to 6 months after a 3-day regimen of third-generation cephalosporins (3GCs). Using ITS1-targeted metagenomics, we highlighted the strong intra- and interindividual diversity of the healthy gut mycobiota. With a specific quantitative approach, we showed that C. albicans prevalence was much higher than previously reported, with all subjects but one being carriers of C. albicans, although with highly variable burdens. 3GCs significantly altered the mycobiota composition and the fungal load was increased both at short and long term. Both C. albicans relative and absolute abundances were increased but 3GCs did not reduce intersubject variability. Variations in C. albicans burden in response to 3GC treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity, with subjects characterized by a high increase of β-lactamase activity displaying a lower increase of C. albicans levels. A same antibiotic treatment might thus affect differentially the gut mycobiota and C. albicans carriage, depending on the treated subject, suggesting a need to adjust the current risk factors for C. albicans overgrowth after a β-lactam treatment. IMPORTANCE Fungal infections are redoubtable healthcare-associated complications in immunocompromised patients. Particularly, the commensal intestinal yeast Candida albicans causes invasive infections in intensive care patients and is, therefore, associated with high mortality. These infections are preceded by an intestinal expansion of C. albicans before its translocation into the bloodstream. Antibiotics are a well-known risk factor for C. albicans overgrowth but the impact of antibiotic-induced dysbiosis on the human gut mycobiota—the fungal microbiota—and the understanding of the mechanisms involved in C. albicans overgrowth in humans are very limited. Our study shows that antibiotics increase the fungal proportion in the gut and disturb the fungal composition, especially C. albicans, in a subject-dependent manner. Indeed, variations across subjects in C. albicans burden in response to β-lactam treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity. This highlighted a potential new key factor for C. albicans overgrowth. Thus, the significance of our research is in providing a better understanding of the factors behind C. albicans intestinal overgrowth, which might lead to new means to prevent life-threatening secondary infections. Antibiotics disturb the intestinal bacterial microbiota, leading to gut dysbiosis and an increased risk for the overgrowth of opportunistic pathogens. It is not fully understood to what extent antibiotics affect the fungal fraction of the intestinal microbiota, the mycobiota. There is no report of the direct role of antibiotics in the overgrowth in healthy humans of the opportunistic pathogenic yeast Candida albicans . Here, we have explored the gut mycobiota of 22 healthy subjects before, during, and up to 6 months after a 3-day regimen of third-generation cephalosporins (3GCs). Using ITS1-targeted metagenomics, we highlighted the strong intra- and interindividual diversity of the healthy gut mycobiota. With a specific quantitative approach, we showed that C. albicans prevalence was much higher than previously reported, with all subjects but one being carriers of C. albicans , although with highly variable burdens. 3GCs significantly altered the mycobiota composition and the fungal load was increased both at short and long term. Both C. albicans relative and absolute abundances were increased but 3GCs did not reduce intersubject variability. Variations in C. albicans burden in response to 3GC treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity, with subjects characterized by a high increase of β-lactamase activity displaying a lower increase of C. albicans levels. A same antibiotic treatment might thus affect differentially the gut mycobiota and C. albicans carriage, depending on the treated subject, suggesting a need to adjust the current risk factors for C. albicans overgrowth after a β-lactam treatment. Fungal infections are redoubtable healthcare-associated complications in immunocompromised patients. Particularly, the commensal intestinal yeast Candida albicans causes invasive infections in intensive care patients and is, therefore, associated with high mortality. Antibiotics disturb the intestinal bacterial microbiota, leading to gut dysbiosis and an increased risk for the overgrowth of opportunistic pathogens. It is not fully understood to what extent antibiotics affect the fungal fraction of the intestinal microbiota, the mycobiota. There is no report of the direct role of antibiotics in the overgrowth in healthy humans of the opportunistic pathogenic yeast Candida albicans . Here, we have explored the gut mycobiota of 22 healthy subjects before, during, and up to 6 months after a 3-day regimen of third-generation cephalosporins (3GCs). Using ITS1-targeted metagenomics, we highlighted the strong intra- and interindividual diversity of the healthy gut mycobiota. With a specific quantitative approach, we showed that C. albicans prevalence was much higher than previously reported, with all subjects but one being carriers of C. albicans , although with highly variable burdens. 3GCs significantly altered the mycobiota composition and the fungal load was increased both at short and long term. Both C. albicans relative and absolute abundances were increased but 3GCs did not reduce intersubject variability. Variations in C. albicans burden in response to 3GC treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity, with subjects characterized by a high increase of β-lactamase activity displaying a lower increase of C. albicans levels. A same antibiotic treatment might thus affect differentially the gut mycobiota and C. albicans carriage, depending on the treated subject, suggesting a need to adjust the current risk factors for C. albicans overgrowth after a β-lactam treatment. IMPORTANCE Fungal infections are redoubtable healthcare-associated complications in immunocompromised patients. Particularly, the commensal intestinal yeast Candida albicans causes invasive infections in intensive care patients and is, therefore, associated with high mortality. These infections are preceded by an intestinal expansion of C. albicans before its translocation into the bloodstream. Antibiotics are a well-known risk factor for C. albicans overgrowth but the impact of antibiotic-induced dysbiosis on the human gut mycobiota—the fungal microbiota—and the understanding of the mechanisms involved in C. albicans overgrowth in humans are very limited. Our study shows that antibiotics increase the fungal proportion in the gut and disturb the fungal composition, especially C. albicans , in a subject-dependent manner. Indeed, variations across subjects in C. albicans burden in response to β-lactam treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity. This highlighted a potential new key factor for C. albicans overgrowth. Thus, the significance of our research is in providing a better understanding of the factors behind C. albicans intestinal overgrowth, which might lead to new means to prevent life-threatening secondary infections. ABSTRACT Antibiotics disturb the intestinal bacterial microbiota, leading to gut dysbiosis and an increased risk for the overgrowth of opportunistic pathogens. It is not fully understood to what extent antibiotics affect the fungal fraction of the intestinal microbiota, the mycobiota. There is no report of the direct role of antibiotics in the overgrowth in healthy humans of the opportunistic pathogenic yeast Candida albicans. Here, we have explored the gut mycobiota of 22 healthy subjects before, during, and up to 6 months after a 3-day regimen of third-generation cephalosporins (3GCs). Using ITS1-targeted metagenomics, we highlighted the strong intra- and interindividual diversity of the healthy gut mycobiota. With a specific quantitative approach, we showed that C. albicans prevalence was much higher than previously reported, with all subjects but one being carriers of C. albicans, although with highly variable burdens. 3GCs significantly altered the mycobiota composition and the fungal load was increased both at short and long term. Both C. albicans relative and absolute abundances were increased but 3GCs did not reduce intersubject variability. Variations in C. albicans burden in response to 3GC treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity, with subjects characterized by a high increase of β-lactamase activity displaying a lower increase of C. albicans levels. A same antibiotic treatment might thus affect differentially the gut mycobiota and C. albicans carriage, depending on the treated subject, suggesting a need to adjust the current risk factors for C. albicans overgrowth after a β-lactam treatment. IMPORTANCE Fungal infections are redoubtable healthcare-associated complications in immunocompromised patients. Particularly, the commensal intestinal yeast Candida albicans causes invasive infections in intensive care patients and is, therefore, associated with high mortality. These infections are preceded by an intestinal expansion of C. albicans before its translocation into the bloodstream. Antibiotics are a well-known risk factor for C. albicans overgrowth but the impact of antibiotic-induced dysbiosis on the human gut mycobiota—the fungal microbiota—and the understanding of the mechanisms involved in C. albicans overgrowth in humans are very limited. Our study shows that antibiotics increase the fungal proportion in the gut and disturb the fungal composition, especially C. albicans, in a subject-dependent manner. Indeed, variations across subjects in C. albicans burden in response to β-lactam treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity. This highlighted a potential new key factor for C. albicans overgrowth. Thus, the significance of our research is in providing a better understanding of the factors behind C. albicans intestinal overgrowth, which might lead to new means to prevent life-threatening secondary infections. Antibiotics disturb the intestinal bacterial microbiota, leading to gut dysbiosis and an increased risk for the overgrowth of opportunistic pathogens. It is not fully understood to what extent antibiotics affect the fungal fraction of the intestinal microbiota, the mycobiota. There is no report of the direct role of antibiotics in the overgrowth in healthy humans of the opportunistic pathogenic yeast Candida albicans. Here, we have explored the gut mycobiota of 22 healthy subjects before, during, and up to 6 months after a 3-day regimen of third-generation cephalosporins (3GCs). Using ITS1-targeted metagenomics, we highlighted the strong intra- and interindividual diversity of the healthy gut mycobiota. With a specific quantitative approach, we showed that C. albicans prevalence was much higher than previously reported, with all subjects but one being carriers of C. albicans, although with highly variable burdens. 3GCs significantly altered the mycobiota composition and the fungal load was increased both at short and long term. Both C. albicans relative and absolute abundances were increased but 3GCs did not reduce intersubject variability. Variations in C. albicans burden in response to 3GC treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity, with subjects characterized by a high increase of β-lactamase activity displaying a lower increase of C. albicans levels. A same antibiotic treatment might thus affect differentially the gut mycobiota and C. albicans carriage, depending on the treated subject, suggesting a need to adjust the current risk factors for C. albicans overgrowth after a β-lactam treatment. IMPORTANCE Fungal infections are redoubtable healthcare-associated complications in immunocompromised patients. Particularly, the commensal intestinal yeast Candida albicans causes invasive infections in intensive care patients and is, therefore, associated with high mortality. These infections are preceded by an intestinal expansion of C. albicans before its translocation into the bloodstream. Antibiotics are a well-known risk factor for C. albicans overgrowth but the impact of antibiotic-induced dysbiosis on the human gut mycobiota-the fungal microbiota-and the understanding of the mechanisms involved in C. albicans overgrowth in humans are very limited. Our study shows that antibiotics increase the fungal proportion in the gut and disturb the fungal composition, especially C. albicans, in a subject-dependent manner. Indeed, variations across subjects in C. albicans burden in response to β-lactam treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity. This highlighted a potential new key factor for C. albicans overgrowth. Thus, the significance of our research is in providing a better understanding of the factors behind C. albicans intestinal overgrowth, which might lead to new means to prevent life-threatening secondary infections.Antibiotics disturb the intestinal bacterial microbiota, leading to gut dysbiosis and an increased risk for the overgrowth of opportunistic pathogens. It is not fully understood to what extent antibiotics affect the fungal fraction of the intestinal microbiota, the mycobiota. There is no report of the direct role of antibiotics in the overgrowth in healthy humans of the opportunistic pathogenic yeast Candida albicans. Here, we have explored the gut mycobiota of 22 healthy subjects before, during, and up to 6 months after a 3-day regimen of third-generation cephalosporins (3GCs). Using ITS1-targeted metagenomics, we highlighted the strong intra- and interindividual diversity of the healthy gut mycobiota. With a specific quantitative approach, we showed that C. albicans prevalence was much higher than previously reported, with all subjects but one being carriers of C. albicans, although with highly variable burdens. 3GCs significantly altered the mycobiota composition and the fungal load was increased both at short and long term. Both C. albicans relative and absolute abundances were increased but 3GCs did not reduce intersubject variability. Variations in C. albicans burden in response to 3GC treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity, with subjects characterized by a high increase of β-lactamase activity displaying a lower increase of C. albicans levels. A same antibiotic treatment might thus affect differentially the gut mycobiota and C. albicans carriage, depending on the treated subject, suggesting a need to adjust the current risk factors for C. albicans overgrowth after a β-lactam treatment. IMPORTANCE Fungal infections are redoubtable healthcare-associated complications in immunocompromised patients. Particularly, the commensal intestinal yeast Candida albicans causes invasive infections in intensive care patients and is, therefore, associated with high mortality. These infections are preceded by an intestinal expansion of C. albicans before its translocation into the bloodstream. Antibiotics are a well-known risk factor for C. albicans overgrowth but the impact of antibiotic-induced dysbiosis on the human gut mycobiota-the fungal microbiota-and the understanding of the mechanisms involved in C. albicans overgrowth in humans are very limited. Our study shows that antibiotics increase the fungal proportion in the gut and disturb the fungal composition, especially C. albicans, in a subject-dependent manner. Indeed, variations across subjects in C. albicans burden in response to β-lactam treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity. This highlighted a potential new key factor for C. albicans overgrowth. Thus, the significance of our research is in providing a better understanding of the factors behind C. albicans intestinal overgrowth, which might lead to new means to prevent life-threatening secondary infections. |
| Author | Burdet, Charles Volant, Stevenn Duval, Xavier Sertour, Natacha Devente, Savannah Docquier, Jean-Denis Grall, Nathalie Ghozlane, Amine Delavy, Margot Mentré, France Bougnoux, Marie-Elisabeth d’Enfert, Christophe |
| Author_xml | – sequence: 1 givenname: Margot surname: Delavy fullname: Delavy, Margot organization: Institut Pasteur, Université Paris Cité, INRAE USC2019, Unité Biologie et Pathogénicité Fongiques, Paris, France – sequence: 2 givenname: Charles surname: Burdet fullname: Burdet, Charles organization: Université Paris Cité, IAME, INSERM, Paris, France, AP-HP, Département d’Epidémiologie, Biostatistique et Recherche Clinique, Hôpital Bichat, Paris, France – sequence: 3 givenname: Natacha surname: Sertour fullname: Sertour, Natacha organization: Institut Pasteur, Université Paris Cité, INRAE USC2019, Unité Biologie et Pathogénicité Fongiques, Paris, France – sequence: 4 givenname: Savannah surname: Devente fullname: Devente, Savannah organization: Università di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italy – sequence: 5 givenname: Jean-Denis orcidid: 0000-0001-9483-4476 surname: Docquier fullname: Docquier, Jean-Denis organization: Università di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italy – sequence: 6 givenname: Nathalie surname: Grall fullname: Grall, Nathalie organization: Université Paris Cité, IAME, INSERM, Paris, France – sequence: 7 givenname: Stevenn surname: Volant fullname: Volant, Stevenn organization: Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Paris, France – sequence: 8 givenname: Amine surname: Ghozlane fullname: Ghozlane, Amine organization: Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Paris, France – sequence: 9 givenname: Xavier surname: Duval fullname: Duval, Xavier organization: Université Paris Cité, IAME, INSERM, Paris, France, Clinical investigation center, INSERM 1425, IAME, Hôpital Bichat, Assistance Publique des Hôpitaux de Paris (APHP), Université Paris Cité, Paris, France – sequence: 10 givenname: France surname: Mentré fullname: Mentré, France organization: Université Paris Cité, IAME, INSERM, Paris, France, AP-HP, Département d’Epidémiologie, Biostatistique et Recherche Clinique, Hôpital Bichat, Paris, France – sequence: 11 givenname: Christophe orcidid: 0000-0002-6235-3886 surname: d’Enfert fullname: d’Enfert, Christophe organization: Institut Pasteur, Université Paris Cité, INRAE USC2019, Unité Biologie et Pathogénicité Fongiques, Paris, France – sequence: 12 givenname: Marie-Elisabeth surname: Bougnoux fullname: Bougnoux, Marie-Elisabeth organization: Institut Pasteur, Université Paris Cité, INRAE USC2019, Unité Biologie et Pathogénicité Fongiques, Paris, France, Unité de Parasitologie-Mycologie, Service de Microbiologie Clinique, Hôpital Necker-Enfants-Malades, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36448778$$D View this record in MEDLINE/PubMed https://pasteur.hal.science/pasteur-04017287$$DView record in HAL |
| BookMark | eNp1ksFu1DAQhiNUREvpkSvyESGl2E4cJxekaNttV1oEgsLVcpxJ11Vib21npX0tbrwEz4Sz20JbQS6JJt989oz-l8mBsQaS5DXBp4TQ8v3QaHuKaVnilNJnyRElDKecEXLw4PswOfH-Bscny0iZ4RfJYVbkecl5eZT8rNGs10Yr2aOvYWy36LOzG92CR2EFaK6dD-hMO1ABnU91owBdrWRACxPAadPqWB1j93fptAzaGo-0QXOYjL9-pEupghykB1SrENmwRXXXTbrJfzEG9HGrbJwjSHS2NXLQaif4An4dXYCC_atBtQl6YiP0Knneyd7Dyd37OPk2P7-aXabLTxeLWb1MZc6KkKquqUgFtIVKAqegqo50rKOlqghvWEOKnJUFQJPFjWKeScBdXFQjJYeGEZodJ4u9t7XyRqydHqTbCiu12BWsuxbSxQv1IHiTdwqqqsItzaWiJeQqm85VAIwxHF0f9q712AzQKjDByf6R9PEfo1fi2m5ExQuW8ywK0r1g9aTtsl6KtfQBRidwjgmnJd-QyL-9O9DZ2xF8EIP2CvpeGrCjF5TnGcOMl0VE3-1R6QcqbuzoTFyrIFhMURNT1MQuaoJOS3nzcJA_V7kPVgSyPaCc9d5BJ5QOu3jEuXT_X236pOte_G_-N6dD9n4 |
| CitedBy_id | crossref_primary_10_1016_j_tim_2023_08_002 crossref_primary_10_3390_jof9111105 crossref_primary_10_1186_s40168_023_01746_0 crossref_primary_10_1002_jmv_29601 crossref_primary_10_1016_j_tim_2023_08_003 crossref_primary_10_1093_femsec_fiae113 crossref_primary_10_3390_jof10030192 crossref_primary_10_1080_19490976_2023_2287618 crossref_primary_10_3390_antibiotics12101475 crossref_primary_10_1016_j_biomaterials_2024_122525 |
| Cites_doi | 10.1038/nm.3871 10.1038/srep25945 10.2144/04365ST04 10.1053/j.gastro.2020.05.048 10.1016/j.cell.2021.01.016 10.1186/1471-2180-12-56 10.1186/s40168-020-00899-6 10.1128/CVI.00200-08 10.1086/323759 10.1136/jcp.54.5.362 10.1128/AAC.00789-12 10.1038/s41396-020-00848-z 10.1128/AAC.02244-18 10.1371/journal.pone.0071806 10.7554/eLife.49206 10.1038/s41467-021-22845-2 10.1136/gutjnl-2015-310746 10.1093/infdis/160.2.274 10.1126/scitranslmed.3004404 10.1111/j.1365-294x.1993.tb00005.x 10.1093/femsre/fuaa060 10.1038/nrdp.2016.20 10.1007/978-3-319-24277-4 10.1128/AAC.00820-19 10.1002/yea.3368 10.1186/gm467 10.1038/nature08821 10.1016/j.chom.2022.04.013 10.1016/j.cell.2022.01.017 10.1038/s41467-018-06103-6 10.1038/nrmicro3380 10.1128/JCM.44.5.1810-1820.2006 10.1186/s40168-017-0373-4 10.1128/IAI.00469-16 10.1016/j.mib.2016.08.006 10.1038/nature06244 10.1186/s12859-020-03666-4 10.1016/j.chom.2020.03.006 |
| ContentType | Journal Article |
| Copyright | Copyright © 2022 Delavy et al. Attribution Copyright © 2022 Delavy et al. 2022 Delavy et al. |
| Copyright_xml | – notice: Copyright © 2022 Delavy et al. – notice: Attribution – notice: Copyright © 2022 Delavy et al. 2022 Delavy et al. |
| CorporateAuthor | PrediRes Study Group |
| CorporateAuthor_xml | – name: PrediRes Study Group |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 1XC VOOES 5PM DOA |
| DOI | 10.1128/mbio.02880-22 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2150-7511 |
| Editor | Heitman, Joseph |
| Editor_xml | – sequence: 1 givenname: Joseph surname: Heitman fullname: Heitman, Joseph |
| ExternalDocumentID | oai_doaj_org_article_7b4fce9990d24ac28e4c3e9aecee5550 PMC9765473 oai_HAL_pasteur_04017287v1 02880-22 36448778 10_1128_mbio_02880_22 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Assistance Publique - Hôpitaux de Paris (AP-HP) grantid: CEREMI CRC13-179 funderid: https://doi.org/10.13039/501100002738 – fundername: EC | H2020 | PRIORITY 'Excellent science' | H2020 Marie Skłodowska-Curie Actions (MSCA) grantid: FunHoMic grant No. 812969 funderid: https://doi.org/10.13039/100010665 – fundername: Investissement d'Avenir Program grantid: Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases - ANR10-LABX-62-IBEID – fundername: Agence Nationale de la Recherche (ANR) grantid: FunComPath ANR-14-IFEC-0004 funderid: https://doi.org/10.13039/501100001665 – fundername: Agence Nationale de la Recherche (ANR) grantid: PrediRes ANR-16-CE15-0022 funderid: https://doi.org/10.13039/501100001665 – fundername: ; grantid: Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases - ANR10-LABX-62-IBEID – fundername: ; grantid: CEREMI CRC13-179 – fundername: ; grantid: FunHoMic grant No. 812969 – fundername: ; grantid: PrediRes ANR-16-CE15-0022 – fundername: ; grantid: FunComPath ANR-14-IFEC-0004 |
| GroupedDBID | --- 0R~ 53G 5VS AAFWJ AAGFI AAUOK AAYXX ADBBV AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BTFSW CITATION DIK E3Z EBS FRP GROUPED_DOAJ GX1 H13 HYE HZ~ KQ8 M48 O5R O5S O9- OK1 P2P PGMZT RHI RNS RPM RSF CGR CUY CVF ECM EIF NPM M~E RHF 7X8 1XC VOOES 5PM |
| ID | FETCH-LOGICAL-a456t-cfb919e2de9ae72ec9f1f5f28c917b5b164586eeb3112073ae0f033baa7eb5123 |
| IEDL.DBID | M48 |
| ISSN | 2150-7511 2161-2129 |
| IngestDate | Wed Aug 27 01:23:36 EDT 2025 Thu Aug 21 18:38:54 EDT 2025 Fri Sep 12 12:37:11 EDT 2025 Thu Jul 10 23:08:55 EDT 2025 Wed Dec 21 06:14:38 EST 2022 Thu Apr 03 06:57:24 EDT 2025 Tue Jul 01 00:57:34 EDT 2025 Thu Apr 24 23:08:26 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Candida albicans gut mycobiota beta-lactamases healthy individuals antibiotics |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0 Attribution: http://creativecommons.org/licenses/by This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a456t-cfb919e2de9ae72ec9f1f5f28c917b5b164586eeb3112073ae0f033baa7eb5123 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 PMCID: PMC9765473 The authors declare no conflict of interest. |
| ORCID | 0000-0002-6235-3886 0000-0001-9483-4476 0000-0001-7670-6235 0000-0003-4721-2740 |
| OpenAccessLink | https://journals.asm.org/doi/10.1128/mbio.02880-22 |
| PMID | 36448778 |
| PQID | 2743505786 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_7b4fce9990d24ac28e4c3e9aecee5550 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9765473 hal_primary_oai_HAL_pasteur_04017287v1 proquest_miscellaneous_2743505786 asm2_journals_10_1128_mbio_02880_22 pubmed_primary_36448778 crossref_citationtrail_10_1128_mbio_02880_22 crossref_primary_10_1128_mbio_02880_22 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-12-20 |
| PublicationDateYYYYMMDD | 2022-12-20 |
| PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-20 day: 20 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | mBio |
| PublicationTitleAbbrev | mBio |
| PublicationTitleAlternate | mBio |
| PublicationYear | 2022 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_39_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_12_2 e_1_3_3_37_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_14_2 e_1_3_3_35_2 Krajmalnik-Brown R (e_1_3_3_2_2) 2015; 26 e_1_3_3_32_2 e_1_3_3_33_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_10_2 e_1_3_3_31_2 e_1_3_3_40_2 e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_24_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_45_2 e_1_3_3_25_2 Pappas PG (e_1_3_3_18_2) 2018; 4 e_1_3_3_20_2 e_1_3_3_43_2 e_1_3_3_44_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 e_1_3_3_3_2 e_1_3_3_21_2 e_1_3_3_42_2 B42 Brown, GD, Denning, DW, Gow, NAR, Levitz, SM, Netea, MG, White, TC (B16) 2012; 4 d’Enfert, C, Kaune, AK, Alaban, LR, Chakraborty, S, Cole, N, Delavy, M, Kosmala, D, Marsaux, B, Fróis-Martins, R, Morelli, M, Rosati, D, Valentine, M, Xie, Z, Emritloll, Y, Warn, PA, Bequet, F, Bougnoux, ME, Bornes, S, Gresnigt, MS, Hube, B, Jacobsen, ID, Legrand, M, Leibundgut-Landmann, S, Manichanh, C, Munro, CA, Netea, MG, Queiroz, K, Roget, K, Thomas, V, Thoral, C, Van den Abbeele, P, Walker, AW, Brown, AJP (B18) 2021; 45 Yu, Z, Morrison, M (B34) 2004; 36 B44 Krajmalnik-Brown, R, Lozupone, C, Kang, D-W, Adams, JB (B1) 2015; 26 Fröhlich-Wyder, MT, Arias-Roth, E, Jakob, E (B27) 2019; 36 Tan, CT, Xu, X, Qiao, Y, Wang, Y (B23) 2021; 12 Liu, CM, Kachur, S, Dwan, MG, Abraham, AG, Aziz, M, Hsueh, PR, Huang, YT, Busch, JD, Lamit, LJ, Gehring, CA, Keim, P, Price, LB (B39) 2012; 12 Guiver, M, Levi, K, Oppenheim, BA (B40) 2001; 54 Fan, D, Coughlin, LA, Neubauer, MM, Kim, J, Kim, MS, Zhan, X, Simms-Waldrip, TR, Xie, Y, Hooper, LV, Koh, AY (B14) 2015; 21 Nucci, M, Anaissie, E (B31) 2001; 33 Seelbinder, B, Chen, J, Brunke, S, Vazquez-Uribe, R, Santhaman, R, Meyer, AC, De Oliveira Lino, FS, Chan, KF, Loos, D, Imamovic, L, Tsang, CC, Lam, RPK, Sridhar, S, Kang, K, Hube, B, Woo, PCY, Sommer, MOA, Panagiotou, G (B6) 2020; 8 Mirhakkak, MH, Schäuble, S, Klassert, TE, Brunke, S, Brandt, P, Loos, D, Uribe, RV, Senne de Oliveira Lino, F, Ni, Y, Vylkova, S, Slevogt, H, Hube, B, Weiss, GJ, Sommer, MOA, Panagiotou, G (B15) 2021; 15 Doron, I, Leonardi, I, Li, XV, Fiers, WD, Semon, A, Bialt-DeCelie, M, Migaud, M, Gao, IH, Lin, WY, Kusakabe, T, Puel, A, Iliev, ID (B29) 2021; 184 Drummond, RA, Desai, JV, Ricotta, EE, Swamydas, M, Deming, C, Conlan, S, Quinones, M, Matei-Rascu, V, Sherif, L, Lecky, D, Lee, CCR, Green, NM, Collins, N, Zelazny, AM, Prevots, DR, Bending, D, Withers, D, Belkaid, Y, Segre, JA, Lionakis, MS (B24) 2022; 30 Gardes, M, Bruns, TD (B36) 1993; 2 Smits, WK, Lyras, D, Lacy, DB, Wilcox, MH, Kuijper, EJ (B9) 2016; 2 Sokol, H, Leducq, V, Aschard, H, Pham, HP, Jegou, S, Landman, C, Cohen, D, Liguori, G, Bourrier, A, Nion-Larmurier, I, Cosnes, J, Seksik, P, Langella, P, Skurnik, D, Richard, ML, Beaugerie, L (B25) 2017; 66 da Silva Dantas, A, Lee, KK, Raziunaite, I, Schaefer, K, Wagener, J, Yadav, B, Gow, NA (B22) 2016; 34 Leonardi, I, Gao, IH, Lin, WY, Allen, M, Li, XV, Fiers, WD, De Celie, MB, Putzel, GG, Yantiss, RK, Johncilla, M, Colak, D, Iliev, ID (B28) 2022; 185 Volant, S, Lechat, P, Woringer, P, Motreff, L, Campagne, P, Malabat, C, Kennedy, S, Ghozlane, A (B38) 2020; 21 Milani, C, Ticinesi, A, Gerritsen, J, Nouvenne, A, Lugli, GA, Mancabelli, L, Turroni, F, Duranti, S, Mangifesta, M, Viappiani, A, Ferrario, C, Maggio, M, Lauretani, F, De Vos, W, van Sinderen, D, Meschi, T, Ventura, M (B2) 2016; 6 Fouhy, F, Guinane, CM, Hussey, S, Wall, R, Ryan, CA, Dempsey, EM, Murphy, B, Ross, RP, Fitzgerald, GF, Stanton, C, Cotter, PD (B7) 2012; 56 Wickham, H, Chang, W, Henry, L, Pedersen, TL, Takahashi, K, Wilke, C, Woo, K (B43) 2016 Pappas, PG, Lionakis, MS, Arendrup, MC, Ostrosky-Zeichner, L, Kullberg, BJ (B17) 2018; 4 Leonard, F, Andremont, A, Leclerq, B, Labia, R, Tancrede, C (B11) 1989; 160 Qin, J, Li, R, Raes, J, Arumugam, M, Burgdorf, KS, Manichanh, C, Nielsen, T, Pons, N, Levenez, F, Yamada, T, Mende, DR, Li, J, Xu, J, Li, S, Li, D, Cao, J, Wang, B, Liang, H, Zheng, H, Xie, Y, Tap, J, Lepage, P, Bertalan, M, Batto, JM, Hansen, T, Le Paslier, D, Linneberg, A, Nielsen, HB, Pelletier, E, Renault, P, Sicheritz-Ponten, T, Turner, K, Zhu, H, Yu, C, Li, S, Jian, M, Zhou, Y, Li, Y, Zhang, X, Li, S, Qin, N, Yang, H, Wang, J, Brunak, S, Doré, J, Guarner, F, Kristiansen, K, Pedersen, O, Parkhill, J, Weissenbach, J (B32) 2010; 464 Zuo, T, Zhang, F, Lui, GCY, Yeoh, YK, Li, AYL, Zhan, H, Wan, Y, Chung, ACK, Cheung, CP, Chen, N, Lai, CKC, Chen, Z, Tso, EYK, Fung, KSC, Chan, V, Ling, L, Joynt, G, Hui, DSC, Chan, FKL, Chan, PKS, Ng, SC (B3) 2020; 159 Burdet, C, Grall, N, Linard, M, Bridier-Nahmias, A, Benhayoun, M, Bourabha, K, Magnan, M, Clermont, O, d’Humières, C, Tenaillon, O, Denamur, E, Massias, L, Tubiana, S, Alavoine, L, Andremont, A, Mentré, F, Duval, X, Andremont, A, Burdet, C, Duval, X, Fantin, B, Grall, N, Marcault, E, Massias, L, Mentré, F, Tubiana, S, Alavoine, L, Benhayoun, M, Djerdjour, F, Ecobichon, J-L, Ilic-Habensus, E, Laparra, A, Mandic, M, Nisus, ME, Raine, S, Ralaimazava, P, Vignali, V, Andremont, A, d’Humières, C, Grall, N, Riberty, J, Bourabha, K, Nahmias, AB, Clermont, O, Denamur, E, Magnan, M, Tenaillon, O, Massias, L, Marcault, E, Schneider, M (B8) 2019; 63 Bougnoux, M-E, Diogo, D, François, N, Sendid, B, Veirmeire, S, Colombel, JF, Bouchier, C, Van Kruiningen, H, d'Enfert, C, Poulain, D (B20) 2006; 44 Nash, AK, Auchtung, TA, Wong, MC, Smith, DP, Gesell, JR, Ross, MC, Stewart, CJ, Metcalf, GA, Muzny, DM, Gibbs, RA, Ajami, NJ, Petrosino, JF (B21) 2017; 5 B37 Cui, L, Morris, A, Ghedin, E (B35) 2013; 5 Zuo, T, Wong, SH, Cheung, CP, Lam, K, Lui, R, Cheung, K, Zhang, F, Tang, W, Ching, JYL, Wu, JCY, Chan, PKS, Sung, JJY, Yu, J, Chan, FKL, Ng, SC (B33) 2018; 9 Dollive, S, Chen, Y-Y, Grunberg, S, Bittinger, K, Hoffmann, C, Vandivier, L, Cuff, C, Lewis, JD, Wu, GD, Bushman, FD (B13) 2013; 8 Turnbaugh, PJ, Ley, RE, Hamady, M, Fraser-Liggett, CM, Knight, R, Gordon, JI (B4) 2007; 449 Niehus, R, van Kleef, E, Mo, Y, Turlej-Rogacka, A, Lammens, C, Carmeli, Y, Goossens, H, Tacconelli, E, Carevic, B, Preotescu, L, Malhotra-Kumar, S, Cooper, BS (B12) 2020; 9 Blair, JMA, Webber, MA, Baylay, AJ, Ogbolu, DO, Piddock, LJV (B10) 2015; 13 Sendid, B, Dotan, N, Nseir, S, Savaux, C, Vandewalle, P, Standaert, A, Zerimech, F, Guery, BP, Dukler, A, Colombe, JF, Poulain, D (B26) 2008; 15 Jabra-Rizk, MA, Kong, EF, Tsui, C, Nguyen, MH, Clancy, CJ, Fidel, PL, Noverr, M (B30) 2016; 84 Burdet, C, Nguyen, TT, Duval, X, Ferreira, S, Andremont, A, Guedj, J, Mentré, F, Ait-Ilalne, B, Alavoine, L, Duval, X, Ecobichon, JL, Ilic-Habensus, E, Laparra, A, Nisus, ME, Ralaimazava, P, Raine, S, Tubiana, S, Vignali, V, Chachaty, E (B5) 2019; 63 Leonardi, I, Paramsothy, S, Doron, I, Semon, A, Kaakoush, NO, Clemente, JC, Faith, JJ, Borody, TJ, Mitchell, HM, Colombel, JF, Kamm, MA, Iliev, ID (B19) 2020; 27 B41 |
| References_xml | – ident: e_1_3_3_15_2 doi: 10.1038/nm.3871 – ident: e_1_3_3_3_2 doi: 10.1038/srep25945 – ident: e_1_3_3_35_2 doi: 10.2144/04365ST04 – ident: e_1_3_3_4_2 doi: 10.1053/j.gastro.2020.05.048 – ident: e_1_3_3_30_2 doi: 10.1016/j.cell.2021.01.016 – volume: 26 year: 2015 ident: e_1_3_3_2_2 article-title: Gut bacteria in children with autism spectrum disorders: challenges and promise of studying how a complex community influences a complex disease publication-title: Microb Ecol Heal Dis – ident: e_1_3_3_40_2 doi: 10.1186/1471-2180-12-56 – ident: e_1_3_3_7_2 doi: 10.1186/s40168-020-00899-6 – ident: e_1_3_3_27_2 doi: 10.1128/CVI.00200-08 – ident: e_1_3_3_32_2 doi: 10.1086/323759 – ident: e_1_3_3_41_2 doi: 10.1136/jcp.54.5.362 – ident: e_1_3_3_42_2 – ident: e_1_3_3_8_2 doi: 10.1128/AAC.00789-12 – ident: e_1_3_3_45_2 – ident: e_1_3_3_16_2 doi: 10.1038/s41396-020-00848-z – ident: e_1_3_3_9_2 doi: 10.1128/AAC.02244-18 – ident: e_1_3_3_14_2 doi: 10.1371/journal.pone.0071806 – ident: e_1_3_3_13_2 doi: 10.7554/eLife.49206 – ident: e_1_3_3_24_2 doi: 10.1038/s41467-021-22845-2 – ident: e_1_3_3_26_2 doi: 10.1136/gutjnl-2015-310746 – ident: e_1_3_3_12_2 doi: 10.1093/infdis/160.2.274 – ident: e_1_3_3_17_2 doi: 10.1126/scitranslmed.3004404 – ident: e_1_3_3_37_2 doi: 10.1111/j.1365-294x.1993.tb00005.x – volume: 4 year: 2018 ident: e_1_3_3_18_2 article-title: Invasive candidiasis publication-title: Nat Rev Dis Prim – ident: e_1_3_3_19_2 doi: 10.1093/femsre/fuaa060 – ident: e_1_3_3_10_2 doi: 10.1038/nrdp.2016.20 – ident: e_1_3_3_44_2 doi: 10.1007/978-3-319-24277-4 – ident: e_1_3_3_6_2 doi: 10.1128/AAC.00820-19 – ident: e_1_3_3_28_2 doi: 10.1002/yea.3368 – ident: e_1_3_3_36_2 doi: 10.1186/gm467 – ident: e_1_3_3_33_2 doi: 10.1038/nature08821 – ident: e_1_3_3_25_2 doi: 10.1016/j.chom.2022.04.013 – ident: e_1_3_3_29_2 doi: 10.1016/j.cell.2022.01.017 – ident: e_1_3_3_34_2 doi: 10.1038/s41467-018-06103-6 – ident: e_1_3_3_38_2 – ident: e_1_3_3_11_2 doi: 10.1038/nrmicro3380 – ident: e_1_3_3_21_2 doi: 10.1128/JCM.44.5.1810-1820.2006 – ident: e_1_3_3_22_2 doi: 10.1186/s40168-017-0373-4 – ident: e_1_3_3_31_2 doi: 10.1128/IAI.00469-16 – ident: e_1_3_3_23_2 doi: 10.1016/j.mib.2016.08.006 – ident: e_1_3_3_5_2 doi: 10.1038/nature06244 – ident: e_1_3_3_43_2 – ident: e_1_3_3_39_2 doi: 10.1186/s12859-020-03666-4 – ident: e_1_3_3_20_2 doi: 10.1016/j.chom.2020.03.006 – volume: 21 start-page: 808 year: 2015 end-page: 814 ident: B14 article-title: Activation of HIF-1α and LL-37 by commensal bacteria inhibits Candida albicans colonization publication-title: Nat Med doi: 10.1038/nm.3871 – volume: 13 start-page: 42 year: 2015 end-page: 51 ident: B10 article-title: Molecular mechanisms of antibiotic resistance publication-title: Nat Rev Microbiol doi: 10.1038/nrmicro3380 – volume: 33 start-page: 1959 year: 2001 end-page: 1967 ident: B31 article-title: Revisiting the source of candidemia: skin or gut? publication-title: Clin Infect Dis doi: 10.1086/323759 – volume: 5 start-page: 153 year: 2017 ident: B21 article-title: The gut mycobiome of the Human Microbiome Project healthy cohort publication-title: Microbiome doi: 10.1186/s40168-017-0373-4 – volume: 12 year: 2021 ident: B23 article-title: A peptidoglycan storm caused by β-lactam antibiotic’s action on host microbiota drives Candida albicans infection publication-title: Nat Commun doi: 10.1038/s41467-021-22845-2 – volume: 15 start-page: 1868 year: 2008 end-page: 1877 ident: B26 article-title: Antibodies against glucan, chitin, and Saccharomyces cerevisiae mannan as new biomarkers of Candida albicans infection that complement tests based on C. albicans mannan publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00200-08 – volume: 160 start-page: 274 year: 1989 end-page: 280 ident: B11 article-title: Use of β-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization publication-title: J Infect Dis doi: 10.1093/infdis/160.2.274 – volume: 185 start-page: 831 year: 2022 end-page: 846.e14 ident: B28 article-title: Mucosal fungi promote gut barrier function and social behavior via Type 17 immunity publication-title: Cell doi: 10.1016/j.cell.2022.01.017 – volume: 84 start-page: 2724 year: 2016 end-page: 2739 ident: B30 article-title: Candida albicans pathogenesis: fitting within the host-microbe damage response framework publication-title: Infect Immun doi: 10.1128/IAI.00469-16 – volume: 5 start-page: 63 year: 2013 ident: B35 article-title: The human mycobiome in health and disease publication-title: Genome Med doi: 10.1186/gm467 – volume: 63 year: 2019 ident: B8 article-title: Ceftriaxone and cefotaxime have similar effects on the intestinal microbiota in human volunteers treated by standard-dose regimens publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02244-18 – volume: 36 start-page: 129 year: 2019 end-page: 141 ident: B27 article-title: Cheese yeasts publication-title: Yeast doi: 10.1002/yea.3368 – volume: 8 start-page: 133 year: 2020 ident: B6 article-title: Antibiotics create a shift from mutualism to competition in human gut communities with a longer-lasting impact on fungi than bacteria publication-title: Microbiome doi: 10.1186/s40168-020-00899-6 – volume: 30 start-page: 1020 year: 2022 end-page: 1033.e6 ident: B24 article-title: Long-term antibiotic exposure promotes mortality after systemic fungal infection by driving lymphocyte dysfunction and systemic escape of commensal bacteria publication-title: Cell Host Microbe doi: 10.1016/j.chom.2022.04.013 – volume: 8 year: 2013 ident: B13 article-title: Fungi of the murine gut: episodic variation and proliferation during antibiotic treatment publication-title: PLoS One doi: 10.1371/journal.pone.0071806 – volume: 184 start-page: 1017 year: 2021 end-page: 1031.e14 ident: B29 article-title: Human gut mycobiota tune immunity via CARD9-dependent induction of anti-fungal IgG antibodies publication-title: Cell doi: 10.1016/j.cell.2021.01.016 – volume: 36 start-page: 808 year: 2004 end-page: 812 ident: B34 article-title: Improved extraction of PCR-quality community DNA from digesta and fecal samples publication-title: Biotechniques doi: 10.2144/04365ST04 – volume: 54 start-page: 362 year: 2001 end-page: 366 ident: B40 article-title: Rapid identification of candida species by TaqMan PCR publication-title: J Clin Pathol doi: 10.1136/jcp.54.5.362 – volume: 4 year: 2018 ident: B17 article-title: Invasive candidiasis publication-title: Nat Rev Dis Prim – ident: B37 article-title: 16S Metagenomic Sequencing Library Preparation . https://emea.support.illumina.com/downloads/16s_metagenomic_sequencing_library_preparation.html# . Retrieved 25 August 2021 . – volume: 27 start-page: 823 year: 2020 end-page: 829.e3 ident: B19 article-title: Fungal trans-kingdom dynamics linked to responsiveness to fecal microbiota transplantation (FMT) therapy in ulcerative colitis publication-title: Cell Host Microbe doi: 10.1016/j.chom.2020.03.006 – volume: 12 year: 2012 ident: B39 article-title: FungiQuant: a broad-coverage fungal quantitative real-time PCR assay publication-title: BMC Microbiol doi: 10.1186/1471-2180-12-56 – volume: 34 start-page: 111 year: 2016 end-page: 118 ident: B22 article-title: Cell biology of Candida albicans–host interactions publication-title: Curr Opin Microbiol Curr Opin Microbiol doi: 10.1016/j.mib.2016.08.006 – volume: 6 start-page: 25945 year: 2016 ident: B2 article-title: Gut microbiota composition and Clostridium difficile infection in hospitalized elderly individuals: a metagenomic study publication-title: Sci Rep doi: 10.1038/srep25945 – volume: 15 start-page: 1257 year: 2021 end-page: 1270 ident: B15 article-title: Metabolic modeling predicts specific gut bacteria as key determinants for Candida albicans colonization levels publication-title: ISME J doi: 10.1038/s41396-020-00848-z – volume: 66 start-page: 1039 year: 2017 end-page: 1048 ident: B25 article-title: Fungal microbiota dysbiosis in IBD publication-title: Gut doi: 10.1136/gutjnl-2015-310746 – ident: B41 article-title: R Core Team . 2020 . R: a language and environment for statistical computing . R Foundation for Statistical Computing , Vienna, Austria . – volume: 464 start-page: 59 year: 2010 end-page: 65 ident: B32 article-title: A human gut microbial gene catalogue established by metagenomic sequencing publication-title: Nature doi: 10.1038/nature08821 – volume: 21 year: 2020 ident: B38 article-title: SHAMAN: a user-friendly website for metataxonomic analysis from raw reads to statistical analysis publication-title: BMC Bioinformatics doi: 10.1186/s12859-020-03666-4 – volume: 45 year: 2021 ident: B18 article-title: The impact of the fungus-host-microbiota interplay upon Candida albicans infections: current knowledge and new perspectives publication-title: FEMS Microbiol Rev – volume: 56 start-page: 5811 year: 2012 end-page: 5820 ident: B7 article-title: High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00789-12 – volume: 2 start-page: 16020 year: 2016 ident: B9 article-title: Clostridium difficile infection publication-title: Nat Rev Dis Primers doi: 10.1038/nrdp.2016.20 – volume: 63 year: 2019 ident: B5 article-title: Impact of antibiotic gut exposure on the temporal changes in microbiome diversity publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00820-19 – ident: B42 article-title: Oksanen AJ , Blanchet FG , Friendly M , Kindt R , Legendre P , Mcglinn D , Minchin PR , Hara RBO , Simpson GL , Solymos P , Stevens MHH , Szoecs E . 2019 . Package ‘vegan.’ R Packag Libr . https://CRAN.R-project.org/package=vegan . – volume: 2 start-page: 113 year: 1993 end-page: 118 ident: B36 article-title: ITS primers with enhanced specificity for basidiomycetes - application to the identification of mycorrhizae and rusts publication-title: Mol Ecol doi: 10.1111/j.1365-294x.1993.tb00005.x – volume: 26 year: 2015 ident: B1 article-title: Gut bacteria in children with autism spectrum disorders: challenges and promise of studying how a complex community influences a complex disease publication-title: Microb Ecol Heal Dis – volume: 159 start-page: 944 year: 2020 end-page: 955.e8 ident: B3 article-title: Alterations in gut microbiota of patients with COVID-19 during time of hospitalization publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.05.048 – volume: 9 start-page: 1 year: 2020 end-page: 20 ident: B12 article-title: Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance publication-title: Elife doi: 10.7554/eLife.49206 – volume: 4 start-page: 165rv13 year: 2012 ident: B16 article-title: Hidden killers: human fungal infections publication-title: Sci Transl Med – year: 2016 ident: B43 publication-title: ggplot2: Elegant Graphics for Data Analysis ;Springer-Verlag New York – volume: 449 start-page: 804 year: 2007 end-page: 810 ident: B4 article-title: The Human Microbiome Project publication-title: Nat doi: 10.1038/nature06244 – volume: 44 start-page: 1810 year: 2006 end-page: 1820 ident: B20 article-title: Multilocus sequence typing reveals intrafamilial transmission and microevolutions of Candida albicans isolates from the human digestive tract publication-title: J Clin Microbiol doi: 10.1128/JCM.44.5.1810-1820.2006 – volume: 9 year: 2018 ident: B33 article-title: Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection publication-title: Nat Commun doi: 10.1038/s41467-018-06103-6 – ident: B44 article-title: Ekstrøm CT . 2020 . Miscellaneous esoteric statistical scripts [R package MESS version 0.5.7] . https://CRAN.R-project.org/package=MESS . |
| SSID | ssj0000331830 |
| Score | 2.418158 |
| Snippet | Fungal infections are redoubtable healthcare-associated complications in immunocompromised patients. Particularly, the commensal intestinal yeast
Candida... Antibiotics disturb the intestinal bacterial microbiota, leading to gut dysbiosis and an increased risk for the overgrowth of opportunistic pathogens. It is... ABSTRACT Antibiotics disturb the intestinal bacterial microbiota, leading to gut dysbiosis and an increased risk for the overgrowth of opportunistic pathogens.... |
| SourceID | doaj pubmedcentral hal proquest asm2 pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0288022 |
| SubjectTerms | Anti-Bacterial Agents antibiotics beta-Lactamases Candida albicans Candida albicans - physiology Dysbiosis Editor's Pick gut mycobiota healthy individuals Human Microbiome Humans Life Sciences Monobactams Research Article |
| SummonAdditionalLinks | – databaseName: American Society for Microbiology Open Access dbid: AAUOK link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLamTUi8IO50DGQE4omM1Lk5j-FSKtgAoRXtzbIdR420JtOaTurf4o0_wW_ic5wEMjSJ19Y9UX2Oz_k-51wIeRHmRRDEqfG4VMYLFXSheJx7jEsDlywR5ew95PHneL4IP55GpzuE9bUw3Q6uD-V61b7IH042469XqqwPERC57zG43b0IcB-Eay_LFl8-DTcrfmDt1O8bal79HXwvZLNRHGrb9SO6LG0y5L9I82rC5F8RaHab3OqgI82cru-QHVPdJTfcMMntPfIzo12TzzNqswO39KursltTgDw6K4HzqPNwtJ8lSk-WsqHtrWA5VGbR7-DP7iKPlhWdGSvx1w_vSOpGrhD1aKbdzAmatdkgrfwPm4Yeb7Xt6tRI-s4Num8FfHNpuIY29R8xNKtstUptu0TfJ4vZ-5O3c68bzOBJ4K3G04VKp6lhuUmlSZjRaTEtooJxDfKnIgUKFvHYgKdj--FDpPELaEVJmRgFhBE8ILtVXZlHhEZ-HgaBLqBKPzTgQoCgQFSJVLlmADcT8txqS_R2IVrSwriwOhWtTgVjE_KqV6bQXW9zO2Lj7LrlL4fl566px3UL31jLGBbZXtztB7BM0R1tkaiw0AZA289ZKDXjJtSB3RngjwgEEE-DXY1kzLMjcS5xjDcXAl7UzghLLvFfn_WmJ3DI7ZsbWZl6sxYMOM8ySR5PyENnioO8wDLsJOETkoyMdPTA8TdVuWwbiQOK2tHT-_-1x4_JTWZLP6YMnvWA7DYXG_MEgKxRT7sT-BvVQjdB priority: 102 providerName: American Society for Microbiology – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hSEhcEJRXSosGgThh6qxf66N5hAi1CKEW9bbaXa8VS41dNU6l_C1u_Al-EzO7TohBFReuyWoce2Znvs-Z_Yaxl3FZRVGa20AobYNYoy-0SMuAC2UxJSuscvQe8uRzOjuLP50n5zujvqgnzMsD-wd3lOm4MhZhTFjyWBkubGwimyuL2T1JPFsP83CHTLkcHFGshhtRTS6OFrpu32AxFWFAg3JHarngg1rkJPuxwsypIfJvtPln0-ROFZreY3d7-AiF_9n32S3b7LHbfqDk-gH7UUAv9HkB1CG4hi_-pN0SEOjBtEasBz7LwWaeKJzOVQfuzWC9PZ0F35BD-5d5UDcwtWTx5_fgWJlOLbDyQWH83AkoXEeIs_9x1cHJ2pCyU6fgvR927wx89a24Frr2txkoGjqx0pJS9EN2Nv1w-m4W9MMZAoWYqwtMpfNJbnlJvsi4NXk1qZKKC4MEUCcaaVgiUotcHR8_5hFlwwq9opXKrEaUET1io6Zt7BMGSVjGUWSqhIswtsiHEIYiqsqULg1HgDNmL8hbst9dS-mICxeSfCqdTyXnY_Z640xpen1zGrNxcdPyV9vll17Y46aFbykytotIj9t9gFEq-yiV_4pSvBrG1cDGrDiWlwq38upKYialOWHZNd7r803oSdzo9O-Namy7WkqOWI_YpEjH7LEPxa29iFh2lokxywZBOrjg8JumnjsxcYSjNH56_3_c5VN2h9PpkAnH5HvARt3Vyh4iZuv0M7c9fwGcwUSh priority: 102 providerName: Directory of Open Access Journals |
| Title | A Clinical Study Provides the First Direct Evidence That Interindividual Variations in Fecal β-Lactamase Activity Affect the Gut Mycobiota Dynamics in Response to β-Lactam Antibiotics |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36448778 https://journals.asm.org/doi/10.1128/mbio.02880-22 https://www.proquest.com/docview/2743505786 https://pasteur.hal.science/pasteur-04017287 https://pubmed.ncbi.nlm.nih.gov/PMC9765473 https://doaj.org/article/7b4fce9990d24ac28e4c3e9aecee5550 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELbQrpC4IJZnYamMQJzIkjov54BQeHQr2AWEtqg3y3acbaQ2WdoUkb_FjT_Bb2LGSbpkYSUuPaTWWPGMZ76ZzIOQJ36aeV4YG4dLZRxfAS8UD1OHcWlAJUuwchiHPP4QTqb-u1kwO28p1B7g-p-uHc6Tmq4WB9-_1i_hwr9oCmD486XKywOwk9x1GGjjXfupCLP4WqRvlbKHwosRF7BxrhMBzug6bl6kAMpZrpesZ6hsP38wP3PMlvwbil7MqPzDRI1vkOsttqRJIwx75IopbpKrzbTJ-hb5mdC2C-iCYvpgTT81ZXhrCiiQjnMAgrRRgbQbNkpP5rKiNmyYb0u36BdwsJtIH80LOjZI8dcP50jqSi7BLNJEN0MpaGLTRSz9w01Fj2uNbZ8qSd_UhVzm2hL43OTpGlqV52RoUmA5S4ltpG-T6fjtyeuJ005ucCQAssrRmYpHsWGpiaWJmNFxNsqCjHEN3qEKFPhoAQ8NOPJw_KBkpHEz4JCSMjIKIIh3h-wUZWHuERq4qe95OgsYd30DzhJgVIBckVSpZoB-BuQxckt0kiOsV8O4QJ4Ky1PB2IA865gpdNv8HGdwLC5b_nS7_Kzp-nHZwlcoGdtF2KzbPihXp6K9-yJSfqYNIHE3Zb7UjBtfe3gyAFAC8BBhN5CrHo1JciTOJNzzzUqAmsUhYtE3eNdHnegJ0AL4aUcWptysBQMgiK4mDwfkbiOKW3oeuuBRxAck6glpb8P-P0U-t53GAavibOr7_7HvA3KNYWXIiIHi3Sc71WpjHgJeq9SQ7CbJ9OP7oY13wO_hbDS0t_M3xlNE7Q |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELZWu0JwQbwpTyMQJ7KbOi_nGB6lsO2CUIv2ZtmOowa1yWqTIvVvceNP8JuYiZNAFq3ENXXHiuf1zcQzQ8gLP808L4yNw6Uyjq-AF4qHqcO4NGCSJXg5zEPOT8Lp0v94GpzukbCrhfmGc3nX1aGsNs13fFRsTES38wj50Ubl5SE4Re46DEzvQcBiF-T7IEmWn4777Irroay6XVPNi_8D-wsbsIEvalr2g4dZ4YXIf9HmxUuTf3mhyQ1yvYWPNLH8vkn2THGLXLEDJXe3yc-Eto0-1xRvCO7oZ1tpV1EAenSSA9aj1srRbp4oXaxkTZvMYN5XZ9GvEEPbZB7NCzoxSPHXD2cmdS034Ploou3cCZo0N0Ia-u-3NZ3vNHZ2qiV9a4fdNwS-2Ku4htblHzI0KbBipcRO0XfIcvJu8WbqtMMZHAmYq3Z0puJxbFhqYmkiZnScjbMgY1xDAKgCBWFYwEMDsTocP9gRadwMuKKkjIwClOHdJftFWZj7hAZu6nuezgLGXd9APAQwFFBVJFWqGQCcEXmO3BKtdlWiCVwYF8hT0fBUMDYirzpmCt32N8cxG-vLlr_sl5_Zxh6XLXyNktEvwn7czQMQT9Gqt4iUn2kDYNtNmS8148bXHp4MYJAAgkDYDeRqQGOazMSZBFXenguwpDgnLPoO7_qsEz0Bio5fb2Rhym0lGGA9jCZ5OCL3rCj29DyMsqOIj0g0ENLBhsNfinzVNBMHOIrjpx_81xk_JVeni_lMzD6cHD8k1xiWgowZWNpHZL8-35rHANBq9aTVxt8ghDuS |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLamTiBe0LiXcTEC8URG6tycx8AIhXVjQivam2U7jhppTao1Rerf4o0_wW_inDgJZGgSr6l7ovjcvmOfCyGv_Cz3vDA2DpfKOL4CXigeZg7j0oBJluDl8Bzy-CSczv3P58H5Dgm7Wph2B9cHcr1sLvJRs1dZ3s4j5G-XqqgOwCly12FgencDvCkbkd0kmX856k9XXA9l1e2aal79H9hfoM8Gvqhp2Q8eZoEJkf-izatJk395oXSP3G7hI00sv--QHVPeJTfsQMntPfIzoW2jzwuKGYJbemor7dYUgB5NC8B61Fo52s0TpWcLWdPmZLDoq7PoN4ih7WEeLUqaGqT464czk7qWS_B8NNF27gRNmoyQhv7HTU2Ptxo7O9WSHtph9w2BrzYV19C6-kOGJiVWrFTYKfo-macfzt5PnXY4gyMBc9WOzlU8iQ3LTCxNxIyO80ke5IxrCABVoCAMC3hoIFaH7Qc7Io2bA1eUlJFRgDK8B2RUVqV5RGjgZr7n6RxY6foG4iGAoYCqIqkyzQDgjMlL5JboZEM0gQvjAnkqGp4KxsbkTcdModv-5jhm4-K65a_75Svb2OO6he9QMvpF2I-7eQDSKVr1FpHyc20AbLsZ86Vm3Pjaw50BDBJAEAhvA7ka0JgmM7GSoMqbSwGWFOeERd_hW190oidA0fH2Rpam2qwFA6yH0SQPx-ShFcWenodRdhTxMYkGQjp44fCXslg0zcQBjuL46cf_tcfPyc3Tw1TMPp0c7ZNbDCtBJgwM7RMyqi835ings1o9a5XxN-QdOzc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Clinical+Study+Provides+the+First+Direct+Evidence+That+Interindividual+Variations+in+Fecal+%CE%B2-Lactamase+Activity+Affect+the+Gut+Mycobiota+Dynamics+in+Response+to+%CE%B2-Lactam+Antibiotics&rft.jtitle=mBio&rft.au=Delavy%2C+Margot&rft.au=Burdet%2C+Charles&rft.au=Sertour%2C+Natacha&rft.au=Devente%2C+Savannah&rft.date=2022-12-20&rft.issn=2150-7511&rft.eissn=2150-7511&rft.volume=13&rft.issue=6&rft.spage=e0288022&rft_id=info:doi/10.1128%2Fmbio.02880-22&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2150-7511&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2150-7511&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2150-7511&client=summon |